Zoe Kleinman
Three years ago, the DNA-testing firm 23andMe was a massive success, with a share price higher than Apple's.
But, from those heady days of millions of people rushing to send it saliva samples in return for detailed reports about their ancestry, family connections and genetic make-up, it now finds itself fighting for its survival.